Drug approval promising for people with early Alzheimer’s.

Donanemab, a disease-modifying therapy, offers new hope for individuals in the early stages of Alzheimer’s, with the potential to slow the progression of cognitive decline by targeting the underlying pathology of the disease.

Professor Vicky Vass, CEO of Alzheimer’s Research Australia, said the approval represents a major milestone for the research and clinical community in Australia.

“We are thrilled to see this innovative therapy become available to Australians. For the first time, people living with early-stage Alzheimer’s have access to a treatment that targets the disease itself, not just the symptoms.”

“With dementia now the second leading cause of death in Australia, and the leading cause of death for women, this approval brings renewed urgency to advance research, accelerate diagnosis, and improve outcomes.”

Developed by pharmaceutical company Eli Lilly, donanemab works by stimulating the immune system to target and clear amyloid plaques in the brain, a core characteristic of Alzheimer’s disease.

While promising, Professor Vass stressed that donanemab is not a cure.

“It’s essential to understand that this treatment is only suitable for people in the early stages of Alzheimer’s disease who meet certain clinical criteria. It comes with potential side effects and requires careful monitoring by health professionals.”

“That’s why early and accurate diagnosis is more important than ever. We need to ensure people with memory concerns can access assessment, support and information at the earliest opportunity.”

Professor Ralph Martins, AO, Director of Research at Alzheimer’s Research Australia, described the announcement as transformative.

“This news is a game changer for Alzheimer’s treatment in Australia. Donanemab is the first disease-modifying drug approved in Australia that targets the biological cause of Alzheimer’s. It represents a scientific breakthrough — one that could meaningfully slow cognitive decline and improve quality of life.”

Professor Martins added that the announcement underscores the importance of investment in research and innovation.

“Alzheimer’s Research Australia is at the forefront of dementia research in this country. Continued investment in medical research is critical to discovering new treatments  and ultimately a cure for all forms of dementia.”

“As new treatments become available, we must also ensure our health systems are equipped to deliver them safely and equitably to those who need them most.”

Alzheimer’s Research Australia remains committed to driving bold, evidence-based solutions to the growing impact of Alzheimer’s disease in Australia and beyond.

Together, we can change the future.

Media Enquiries:

Professor Ralph Martins is available for interviews.

Email: admin@alzheimersresearch.org.au

Phone: 08 6457 0253